SEC Form 3 · accession 0002150331-26-000001
Lyell Immunopharma, Inc. · LYEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jarrad Mattieu Aguirre
Officer — Chief Medical Officer
Period of report
Aug 31, 2026
Accepted (ET)
Sep 10, 2026 · 7:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001806952
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 20,279 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $11.64 | holding | — | — | — | — | Feb 12, 2035 | Common Stock | 46,249 | — | D |
| Option (right to buy)F3 | $23.71 | holding | — | — | — | — | Feb 9, 2036 | Common Stock | 35,000 | — | D |
| Option (right to buy)F4 | $19.20 | holding | — | — | — | — | May 10, 2036 | Common Stock | 15,000 | — | D |
Explanation of responses
- F1Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: the RSUs vest quarterly over the thirty month period following July 9, 2026; in each case, subject to the reporting person providing service through the applicable vesting date.
- F225% of the option shares vested on January 31, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.
- F312.5% of the option shares will vest on August 9, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
- F412.5% of the option shares will vest on November 11, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.